Orthox Ltd.: Funding, Investors & Team (Sep 2026)

Founded to commercialise technology developed at Oxford University, Orthox aims to revolutionise the way cartilage injuries are treated. Trauma and erosion of the smooth, stiff cartilage in our joints leads to Osteoarthritis (OA) a debilitating disease, which affects over 300 million patients globally and costs the US economy alone over $128 billion each year. Current therapies to repair damaged cartilage focus either on tissue regeneration or on functional replacement; Orthox’s exceptionally strong, resilient, regenerative hydrogel technology, FibroFix™ achieves both these goals, offering a unique solution for the millions of patients suffering from damage to their joints. Initially targeting the knee, Orthox has developed a compelling set of data on lead product FibroFix™ Cartilage which has secured major awards from multiple funding bodies and will shortly enter clinical trials. FibroFix™ technology will then be rolled out to treat other joints and Orthox also has pipeline developments beyond orthopaedics in which strength and tissue regeneration are key. Pipeline expansion is valuable as growth in the annual global biomaterials market will exceed $250 billion by 2025. Orthopaedic biomaterials will form the largest proportion of this and natural biomaterials, like FibroFix™, will be the fastest growing market segment. Orthox: Reducing Pain, Increasing Mobility, Regenerating Strength™.

Orthox Ltd. has raised $12.4M across 1 round on record. The most recent is a Series A of $12.4M announced in Feb 2022.

Orthox Ltd.'s most recent funding round on record is a Series A of $12.4M, announced in Feb 2022.

Nick Skaer is listed as CEO at Orthox Ltd..

Orthox Ltd. is based in Abingdon, Oxfordshire, United Kingdom.

Orthox Ltd. is in the 11-50 employee band.

Orthox Ltd.'s latest round of $12.4M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.